Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis

被引：0
|
作者：
Becker, J. C.
Pettenkofer, J.
Schmid-Wirlitsch, C. [1 ]
Gooss, A. [2 ]
机构：
[1] Nycomed Deutschland GmbH, Constance, DE, Germany
[2] Nycomed Pharma AG, Dubendorf, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2010年 / 140卷 / 13-14期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：13S / 13S
页数：1
相关论文
共 50 条
  • [21] The phosphodiesterase 4 (PDE4) inhibitor roflumilast improves remyelination in a mouse model for multiple sclerosis
    Schepers, M.
    Mailleux, J.
    Bogie, J.
    van Goethem, N.
    Hellings, N.
    Hendriks, J.
    Prickaerts, J.
    Vanmierlo, T.
    GLIA, 2017, 65 : E361 - E361
  • [22] Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
    Hatzelmann, A
    Schudt, C
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 297 (01): : 267 - 279
  • [23] The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses
    Vanmierlo, Tim
    Creemers, Pim
    Akkerman, Sven
    van Duinen, Marlies
    Sambeth, Anke
    De Vry, Jochen
    Uz, Tolga
    Blokland, Arjan
    Prickaerts, Jos
    BEHAVIOURAL BRAIN RESEARCH, 2016, 303 : 26 - 33
  • [24] Novel Roflumilast analogs as soft PDE4 inhibitors
    Boland, Sandro
    Alen, Jo
    Bourin, Arnaud
    Castermans, Karolien
    Boumans, Nicki
    Panitti, Laura
    Vanormelingen, Jessica
    Leysen, Dirk
    Defert, Olivier
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (18) : 4594 - 4597
  • [25] PDE4 INHIBITOR ROFLUMILAST ATTENUATED RENAL FUNCTIONAL DECLINE AND STRUCTURAL DAMAGE IN THE RAT MODEL FOR CHRONIC KIDNEY DISEASE
    Lau, X.
    Zhang, Y.
    Stapleton, D. I.
    Langham, R. G.
    Kelly, D. J.
    NEPHROLOGY, 2014, 19 : 55 - 55
  • [26] Effects of the Novel Inhaled Phosphodiesterase-4 (PDE4) Inhibitor CHF6001 in Targeting Markers of Inflammation in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
    Singh, D.
    Govoni, M.
    Beeh, K. M.
    Colgan, B.
    Kornmann, O.
    Leaker, B.
    Watz, H.
    Lucci, G.
    Geraci, S.
    Rocco, E. Calabro
    Emirova, A.
    Nandeuil, M. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [27] Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
    Singh, Dave
    Emirova, Aida
    Francisco, Catherine
    Santoro, Debora
    Govoni, Mirco
    Nandeuil, Marie Anna
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [28] Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
    Dave Singh
    Aida Emirova
    Catherine Francisco
    Debora Santoro
    Mirco Govoni
    Marie Anna Nandeuil
    Respiratory Research, 21
  • [29] Effect of Roflumilast, a Selective PDE4 Inhibitor, on Bone Phenotypes in ADO2 Mice
    Alam, Imranul
    Hardman, Sara L.
    Gerard-O'Riley, Rita L.
    Acton, Dena
    Parker, Reginald S.
    Hong, Jung Min
    Bruzzaniti, Angela
    Econs, Michael J.
    CALCIFIED TISSUE INTERNATIONAL, 2024, 114 (04) : 419 - 429
  • [30] In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor
    Bundschuh, DS
    Eltze, M
    Barsig, J
    Wollin, L
    Hatzelmann, A
    Beume, R
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 297 (01): : 280 - 290
12345